{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He M"],"funding":["Tianjin Science and Technology Program","Natural Science Foundation of Tianjin City","Ministry of Science and Technology of the People&apos;s Republic of China","National Natural Science Foundation of China"],"pagination":["806837"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895481"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["Several approaches to expand human hematopoietic stem cells (hHSCs) clinically along with retainable capability of multipotential differentiation have been reported, but only a few have advanced to evaluation in clinical trials, which limits the application of HSC-based therapy. Here we show a phthalide derivative, Levistilide A (LA), can serve as a promising molecule to expand functional human umbilical cord blood (UCB) HSCs <i>ex vivo</i>. An in-house screen identified LA out of nine natural products as an outstanding candidate for hHSCs expansion. Additionally, our data indicated that LA treatment not only increased the numbers of phenotype-defined HSCs, but also enhanced their colony formation ability. Xenotransplantation assays showed that LA treatment could maintain unaffected engraf"],"journal":["Frontiers in pharmacology"],"pubmed_title":["Levistilide A Promotes Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity."],"pmcid":["PMC8895481"],"funding_grant_id":["92068204 81870083 81970105 81872764 81903456","20JCQNJC02080","18ZXXYSY00010","2017YFA0104900 2016YFA0100600"],"pubmed_authors":["Wang C","Yang M","Zhang H","He M","Xu H","Zhang Q","Zhang W","Liu X","Li Y","Ding Y","Zhang Y","Gao Y","Xu S","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Levistilide A Promotes Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity.","description":"Several approaches to expand human hematopoietic stem cells (hHSCs) clinically along with retainable capability of multipotential differentiation have been reported, but only a few have advanced to evaluation in clinical trials, which limits the application of HSC-based therapy. Here we show a phthalide derivative, Levistilide A (LA), can serve as a promising molecule to expand functional human umbilical cord blood (UCB) HSCs <i>ex vivo</i>. An in-house screen identified LA out of nine natural products as an outstanding candidate for hHSCs expansion. Additionally, our data indicated that LA treatment not only increased the numbers of phenotype-defined HSCs, but also enhanced their colony formation ability. Xenotransplantation assays showed that LA treatment could maintain unaffected engraf","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T08:57:28.652Z","creation":"2025-04-04T08:57:28.652Z"},"accession":"S-EPMC8895481","cross_references":{"pubmed":["35250558"],"doi":["10.3389/fphar.2022.806837"]}}